OncTimes Talk Podcast Series
Discussions on NCCN Guidelines for MCL and CLL
Episode 1: Relapsed/refractory CLL after BTKi and BCL2i therapy: liso-cel CAR T cell therapy (TRANSCEND CLL 004 trial)
With Tanya Siddiqi, MD and Alexey Danilov, MD PhD
Dr. Danilov and Dr. Siddiqi discuss the recent approval of Liso-cel CAR T cell therapy, and its key efficacy results on CLL.
Episode 2: Frontline mantle cell lymphoma: Role of BTKi therapy in addition to chemoimmunotherapy (TRIANGLE trial)
With Tanya Siddiqi, MD and Alexey Danilov, MD PhD
Dr. Danilov and Dr. Siddiqi talk about the data and findings concerning the TRIANGLE trial on MCL, and how this affects the younger and older population.
Episode 3: Relapsed/refractory Mantle Cell Lymphoma after covalent BTKi Therapy: Pirtobrutinib
With Tanya Siddiqi, MD and Alexey Danilov, MD PhD
Dr. Danilov and Dr. Siddiqi discuss Relapsed/Refractory MCL, and the current solutions for patients failing novel treatment options.
About the speakers:
- Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly chronic lymphocytic leukemia (CLL) and B cell non-Hodgkin lymphoma (B-NHL).
In addition to her clinical practice, Dr. Siddiqi is also principal investigator on a number of clinical trials evaluating the role of targeted therapies, including gene therapy (CAR T cell therapy) and other novel agents primarily in diseases like CLL and B-NHL.
Dr. Siddiqi earned her medical degree at Aga Khan University Medical College in Karachi, Pakistan. Afterward, she completed an internal medicine residency at University of Connecticut Health Center, followed by fellowships in hematology/oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston) and hematopoietic stem cell transplantation at City of Hope.
- Alexey Danilov, M.D., Ph.D., chose oncology as a career because of its breadth and potential. Oncology, he says, "touches all areas of general medicine" and is a most exciting field because of the many new treatments now emerging.
A board-certified clinician and talented researcher, Dr. Danilov focuses on blood cancers, including chronic lymphocytic leukemia and many forms of lymphoma. He is a Leukemia & Lymphoma Society Scholar in Clinical Research.
A native of Russia, Dr. Danilov earned his medical degree and Ph.D. at Yaroslavl State Medical Academy. He continued his training with a residency at Brown University in Providence, Rhode Island, and a fellowship at Tufts Medical Center in Boston.